10-K: Immunocore Holdings plc Reports Annual Results for 2024, Highlights Strategic Priorities for 2025

Immunocore Holdings plc announces its 2024 financial results, highlighting KIMMTRAK's commercial progress and outlining strategic priorities for 2025, including expanding its melanoma franchise and advancing its clinical portfolio.

Summary

• Immunocore Holdings plc reported its 2024 annual results, showcasing the commercial progress of KIMMTRAK and outlining strategic priorities for 2025.
• The company's strategic priorities for 2025 include building a melanoma franchise, advancing the clinical portfolio, and innovating for sustainable growth.
• KIMMTRAK is approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma (mUM).
• In 2024, KIMMTRAK was launched in 14 additional countries, including Australia, Spain, Poland, and the United Kingdom.
• The company is progressing three late-stage clinical programs, including KIMMTRAK and the PRAME-targeted brenetafusp.
• The company has expanded the ImmTAX platform into autoimmune diseases with two potential first-in-class new bispecific candidates entering the pipeline: IMC-S118AI and IMC-U120AI.
• Revenue from sale of therapies, net increased to $309.989 million in 2024, compared to $238.735 million in 2023 and $140.687 million in 2022.
• R&D expenses increased to $222.151 million in 2024, compared to $163.545 million in 2023 and $101.921 million in 2022.
• The company had a net loss of $51.1 million in 2024, compared to a net loss of $55.3 million in 2023 and $52.5 million in 2022.
• As of December 31, 2024, the company had cash and cash equivalents of $455.7 million and marketable securities of $364.6 million.
• The company expects its existing cash and cash equivalents, along with anticipated revenue from KIMMTRAK, to fund its operating expenses and capital expenditure requirements for at least twelve months.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's positive revenue growth and strategic advancements, there are also increasing expenses and a net loss, creating a balanced outlook.

Positives

• Revenue from sale of therapies, net increased to $309.989 million in 2024, compared to $238.735 million in 2023.
• KIMMTRAK is now approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma (mUM).
• The company has expanded the ImmTAX platform into autoimmune diseases with two potential first-in-class new bispecific candidates entering the pipeline: IMC-S118AI and IMC-U120AI.
• As of December 31, 2024, the company had cash and cash equivalents of $455.7 million and marketable securities of $364.6 million.
• The company's strategic priorities for 2025 include building a melanoma franchise, advancing the clinical portfolio, and innovating for sustainable growth.

Negatives

• The company had a net loss of $51.1 million in 2024, compared to a net loss of $55.3 million in 2023.
• R&D expenses increased to $222.151 million in 2024, compared to $163.545 million in 2023.

Risks

• The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition.
• The company's future prospects are highly dependent on its ability to continue to successfully develop and execute its commercialization strategies for KIMMTRAK and any future products for which it may obtain regulatory approval.
• The company may require substantial additional funding to achieve its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit or terminate its product development efforts.
• The company is heavily dependent on the success of its ImmTAX platform to identify and develop product candidates, and if it or its collaborators are unable to successfully develop and commercialize its platforms or experience significant delays in doing so, its business may be harmed.
• The FDA and comparable foreign regulatory authorities regulatory pathways can be difficult to predict and whether, for example, further unanticipated clinical trials are required, will depend on the data obtained in our ongoing clinical trials.

Future Outlook

Immunocore expects its existing cash and cash equivalents, along with anticipated revenue from KIMMTRAK, to fund its operating expenses and capital expenditure requirements for at least twelve months.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition, with companies like Adaptimmune, Immatics, and others pursuing TCR-based therapeutics.

Comparison to Industry Standards

• The document mentions competitors such as Adaptimmune Therapeutics plc, Immatics Biotechnologies GmbH, Adaptive Biotechnologies Corporation, and others who are developing TCR-based therapeutics.
• It also notes that Immatics, TScan Therapeutics, Inc., and Replay Therapeutics, Inc. are conducting Phase 1 clinical trials of PRAME-directed cellular therapies, indicating a competitive landscape for PRAME-targeted treatments.
• The document references Delcath Systems, Inc.'s approval and U.S. launch of HEPZATO KIT, a liver-directed therapy for uveal melanoma, as a competing product.
• It mentions Ideaya Biosciences, Inc.'s initiation of a registrational Phase 3 clinical trial in high-risk neoadjuvant uveal melanoma, and Replimune Group Inc.'s initiation of a registrational Phase 3 clinical trial in immune-checkpoint nave UM, both anticipated to begin in 2025.

Management Changes

Stakeholder Impact

• Shareholders may experience fluctuations in the value of their ADSs due to market volatility and company-specific factors.
• Employees may benefit from the company's growth and expansion, but may also face increased competition for positions.
• Patients may benefit from the development of new and innovative immunomodulating medicines.
• Suppliers and manufacturers may see increased demand for their products and services as the company expands its operations.

Next Steps

• Reach more mUM patients and deliver KIMMTRAK's lifecycle management program through two ongoing registrational Phase 3 trials (TEBE-AM and the EORTC-sponsored ATOM trial).
• Enroll a third registrational trial, PRISM-MEL-301, evaluating brenetafusp in first-line melanoma.
• Enroll patients in multiple Phase 1 and 1/2 oncology trials with brenetafusp (PRAME-A02), IMC-P115C (PRAME-A02-HLE), IMC-R117C (PIWIL1-A02), and IMC-M113V in HIV.
• Plan to submit a CTA or IND for our two autoimmune disease candidates: IMC-S118AI (PPI x PD1) by year end 2025 and IMC-U120AI (CD1a x PD1) in 2026.

Key Dates